1175 completed, 825 unknown, 544 recruiting, 274 terminated. 1109 Phase 2, 649 Not applicable, 609 Phase 1, 316 Phase 3, 105 Phase 4.
Follow Carcinoma, Hepatocellular: new trials by email Literature Review of Carcinoma, Hepatocellular trials Research Report on Carcinoma, Hepatocellular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration RayAblation - Liver Tumors | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-04-01 | 2026-10-16 |
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. TheraSphere - Hepatocellular Carcinoma (HCC) | Not yet recruiting | Boston Scientific Corporation | 140 | 2027-01-01 | 2026-10-01 | |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review - Hepatocellular Carcinoma (HCC), Liver Cancer, Adult | Phase 2 | Not yet recruiting | University of California, San Francisco | 50 | 2026-12-15 | 2026-10-13 |
| Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma Zanzalintinib, Tegavivint - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 36 | 2026-12-01 | 2026-10-16 |
| Erlotinib for Hepatocellular Carcinoma Chemoprevention erlotinib hydrochloride, Placebo - Cirrhosis, Liver, Advanced Liver Fibrosis | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-12-01 | 2026-06-24 |
| Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma Curative-Intent Liver Resection, Immunotherapy-Based Systemic Maintenance Therapy - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | West China Hospital | 60 | 2026-12-01 | 2026-10-08 |
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer Lenvatinib, Tislelizumab, Gefitinib - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 120 | 2026-11-01 | 2026-09-21 |
| Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs ACE723 - Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic | Phase 1 | Not yet recruiting | Acepodia Biotech, Inc. | 70 | 2026-11-01 | 2026-10-06 |
| STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma (HCC) | Recruiting | Universitaire Ziekenhuizen KU Leuven | 280 | 2026-10-15 | 2026-10-07 | |
| SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 33 | 2026-10-15 | 2026-10-20 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma No investigational intervention. Participants receive standard clinical care. Clinical data, imaging/pathology information, and available biospecimens are collected for research. - Hepatocellular Carcinoma (HCC) | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 500 | 2026-10-12 | 2026-09-24 | |
| GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer GLP1-RA (semaglutide) - Pancreatic Cancer, Colorectal Cancer | Early Phase 1 | Recruiting | University of Arizona | 30 | 2026-10-10 | 2026-09-18 |
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
| Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma | Not yet recruiting | University of Oklahoma | 2000 | 2026-10-01 | 2026-07-29 |
Showing 20 of 3372. Sign in to see all of them.
Liver Neoplasms (523) · Stomach Neoplasms (152) · Neoplasms (149) · Carcinoma, Non-Small-Cell Lung (141) · Colorectal Neoplasms (136) · Carcinoma, Renal Cell (135) · Pancreatic Neoplasms (129) · Cholangiocarcinoma (115) · Melanoma (115) · Liver Cirrhosis (97) · Fibrosis (93) · Neoplasm Metastasis (91) · Esophageal Neoplasms (87) · Breast Neoplasms (83)
Neoplasms by Histologic Type (3365) · Neoplasms by Site (3364) · Adenocarcinoma (3362) · Digestive System Diseases (3362) · Neoplasms, Glandular and Epithelial (3362) · Digestive System Neoplasms (3353) · Carcinoma (3331) · Liver Diseases (3319) · Neoplasms (3223) · Liver Neoplasms (2849) · Pathological Conditions, Signs and Symptoms (482) · Pathologic Processes (441) · Gastrointestinal Diseases (283) · Gastrointestinal Neoplasms (257) · Urogenital Diseases (247)
Sorafenib (224) · lenvatinib (153) · Bevacizumab (140) · Nivolumab (90) · atezolizumab (83) · pembrolizumab (75) · Radiosurgery (74) · sintilimab (65) · durvalumab (64) · Oxaliplatin (60) · Fluorouracil (56) · tislelizumab (48) · Doxorubicin (47) · apatinib (46) · Radiofrequency Ablation (44)
Sun Yat-sen University (167) · National Cancer Institute (NCI) (75) · Seoul National University Hospital (60) · Shanghai Zhongshan Hospital (57) · Eastern Hepatobiliary Surgery Hospital (46) · Fudan University (44) · National Taiwan University Hospital (40) · Assistance Publique - Hôpitaux de Paris (39) · M.D. Anderson Cancer Center (35) · Guangxi Medical University (34) · Bayer (33) · Tianjin Medical University Cancer Institute and Hospital (30) · Second Affiliated Hospital of Guangzhou Medical University (27) · Zhejiang University (27) · Zhongda Hospital (26)
China (1155) · United States (895) · South Korea (277) · France (271) · Taiwan (261) · Italy (197) · Spain (153) · Germany (142) · Canada (121) · Hong Kong (115) · Japan (110) · United Kingdom (107) · Singapore (88) · Belgium (83) · Australia (72)
Ming Shi, MD (21) · Jeong Min Lee, MD (14) · Tim F Greten, M.D. (11) · David Hsieh, MD (7) · Gao-Jun Teng, M.D. (6)
PMID 12049862, PMID 11981766, PMID 12540794, PMID 18650514, PMID 19192962, PMID 19095497, PMID 29628281, PMID 32402160, PMID 34143971, PMID 36852452, PMID 12091661, PMID 21374666, PMID 27932229, PMID 29433850, PMID 29471013, PMID 29875066, PMID 32557715, PMID 32716739, PMID 33538338, PMID 34905388, PMID 14667750, PMID 19766639, PMID 26361969, PMID 30207593, PMID 31070690, PMID 31401903, PMID 35421228, PMID 36529152, PMID 38319892, PMID 39437804, PMID 10207464, PMID 14762851, PMID 16250051, PMID 16495695, PMID 16557381, PMID 16908937, PMID 18477802, PMID 19212170, PMID 19908093, PMID 19949018, PMID 20175033, PMID 20203173, PMID 20590903, PMID 20839057, PMID 22002018, PMID 22424438, PMID 22968066, PMID 23099728, PMID 23269991, PMID 23393196
2023 (16), 2016 (11), 2017 (10), 2018 (10), 2019 (10), P30CA016672 (10), P30CA060553 (9), 2025 (8), P30CA015083 (8), 2009 (7), 2014 (7), P30CA014089 (7), P30CA033572 (7), 2015 (6), N01CM62201 (5)